39 studies found for:    " August 15, 2011":" September 14, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Improving Uptake of Early Infant Diagnosis of HIV for the Prevention of Mother-to-child Transmission of HIV
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome
Intervention: Other: Text message
2 Completed Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome;   Disease Progression;   Immune System Diseases;   Malaria;   Parasitic Diseases;   Pneumonia;   Diarrhea;   Infectious Disorder of Immune System
Intervention: Other: Discontinue TMP/SMZ prophylaxis
3 Recruiting HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
Conditions: HIV Infection;   Hepatitis C
Intervention:
4 Completed The Prevalence of Neurocognitive Disorder in a Primary Care-based HIV Cohort Compared to a HIV-negative Control Cohort -
Condition: HIV-1-Associated Cognitive Motor Complex
Intervention:
5 Completed An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART
Condition: Human Immunodeficiency Virus; HIV
Interventions: Drug: Darunavir/Ritonavir (DRV/r);   Drug: Efavirenz (EFV)
6 Terminated Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy
Conditions: Human Immunodeficiency Virus;   Lipohypertrophy
Intervention: Drug: Raltegravir-Maraviroc
7 Active, not recruiting Drug Exposure Registry for GSK2248761, an Investigational NNRTI
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: GSK2248761
8 Unknown  Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals
Condition: HIV Infection
Intervention: Drug: Polyphenon E
9 Recruiting Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects
Condition: HIV Infections
Interventions: Biological: HIVAX;   Biological: saline solution;   Biological: Saline solution
10 Withdrawn Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial
Conditions: Immune Reconstitution Inflammatory Syndrome;   Immune Reconstitution Syndrome;   Tuberculosis;   HIV-infection/Aids
Interventions: Drug: Dexamethasone;   Drug: Atorvastatin;   Drug: Naproxen;   Drug: Placebo
11 Active, not recruiting Vitamin D Supplementation in HIV
Condition: HIV-infection/Aids
Interventions: Dietary Supplement: Vitamin D3;   Dietary Supplement: Placebo
12 Recruiting Implementation of Nucleic Acid Amplification Testing Screening to Identify Acute and Early HIV Infection
Condition: Acute HIV Infection
Intervention: Other: Nucleic Acid Amplification Testing
13 Unknown  Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure
Condition: Human Immunodeficiency Virus (HIV)
Intervention: Behavioral: Enhanced Treatment Support (ETS)
14 Completed Drug Interaction Study Between Dolutegravir and Prednisone
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir;   Drug: Prednisone
15 Completed A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects
Condition: Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions: Drug: GSK1265744 injectable suspension;   Other: Placebo to match injectable suspension
16 Active, not recruiting Screening for Tuberculosis in HIV-infected Patients Eligible for Antiretroviral Treatment
Conditions: HIV Infection;   Tuberculosis
Intervention:
17 Completed Safety Study of Maraviroc's Effect on Human Osteoclasts
Conditions: HIV Infections;   AIDS
Intervention: Drug: Maraviroc
18 Completed Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)
Condition: HIV Infections
Interventions: Biological: Sub C gp140 Vaccine;   Biological: MF59C.1 Adjuvant;   Other: Sodium chloride
19 Active, not recruiting Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV;   Biological: AIDSVAX B/E;   Biological: ALVAC-HIV Placebo;   Biological: AIDSVAX B/E Placebo
20 Unknown  Efficacy of Neuro-HAART in Patients With HIV
Condition: HIV
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results    Last Page
Indicates status has not been verified in more than two years